Received Feb 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | — |
No additional adverse event; HCP calling to report an AE regarding the GARDASIL 9 vaccine. HCP reported that an 19 year old male patient received his first dose of the vaccine on 12/21/2023 at 17 years of age. HCP stated that the patient received his second dose of the vaccine o; This spontaneous report has been received from a pharmacist, regarding to a 19-year-old male patient. The patient's pertinent medical history, concurrent conditions, concomitant medications, and previous drug reactions or allergies were not reported. On 21-DEC-2023, the patient was vaccinated with the first dose (at the age of 17-years old) of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) suspension for injection as prophylaxis (Lot No., expiration date, exact dose quantity volume, route and anatomical location of administration and vaccination scheme frequency were not provided). On 10-FEB-2025, the patient was vaccinated with the second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) suspension for injection as prophylaxis (Lot No., expiration date, exact dose quantity volume, route and anatomical location of administration and vaccination scheme frequency were not provided). It was stated that the pharmacist did not know the reason for the delay between the first and second doses of the mention vaccine. (Inappropriate schedule of product administration). No additional adverse events were reported (No adverse event).